Serial No.: 10/619055 - 2 - Art Unit: 1632

Conf. No.: 6885

and

In the Claims

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1. (Currently Amended) A method for the accelerated production of transgenic animals homozygous for a selected trait comprising:

transfecting a non-human mammalian <u>cell or</u> cell-line with a given transgene construct containing at least one DNA encoding a desired gene;

selecting a <u>cell or cell line(s)</u> in which the desired gene has been inserted into the genome of that cell or cell-line;

performing a first nuclear transfer procedure <u>using the selected cell or cell line as donor</u> <u>nuclei or donor cell nucleus</u>, to generate a first transgenic animal heterozygous for the desired gene;

characterizing the genetic composition of said first heterozygous transgenic animal; selecting cells homozygous for the desired transgene through the use of a selective agent; characterizing surviving cells or cell colonies using known molecular biology methods;

picking surviving cells or cell colonies eells for use in a second round of nuclear transfer or embryo transfer; and

producing a second transgenic animal homozygous for a desired transgene.

- 2. (Original) The method of claim 1, wherein said first transgenic animal is biopsied so as to characterize the genome of said first transgenic animal.
- 3. (Currently Amended) The method of claim 2, wherein the cells or cell line biopsied from said first transgenic animal is expanded through cell culture techniques.
- 4. (Currently Amended) The method of claim 1, wherein said surviving cells or cell colonies are characterized by one of several known molecular biology methods including without limitation-FISH, Southern Blot, or PCR.

Serial No.: 10/619055 - 3 - Art Unit: 1632

Conf. No.: 6885

5. (Currently Amended) The method of claim 1, wherein the homozygous transgenic animal[[s]] are more quickly is developed for xenotransplantation purposes or developed with humanized Ig loci.

- 6. (Currently Amended) The method of claim 1, wherein said <u>non-human mammalian cell or cell line donor differentiated mammalian cell to be used as a source of donor nuclei or donor cell nucleus</u> is from an ungulate.
- 7. (Currently Amended) The method of claim 1-or-6, wherein said donor cell or donor cell nucleus is from anthe ungulate is a selected from the group consisting of bovine, ovine, porcine, equine, caprine andor buffalo.
- 8. (Currently Amended) The method of claim 1, wherein said <u>non-human mammalian cell or cell line donor differentiated mammalian cell to be used as a source of donor nuclei or donor cell nucleus</u>-is from an adult non-human mammalian somatic cell.
- 9. (Currently Amended) The method of claim 1, wherein said non-human mammal<u>ian cell or cell line</u> is a rodent <u>cell or cell line</u>.
- 10. (Currently Amended) The method of claim 1, wherein said <u>non-human mammalian cell or cell-line</u> donor differentiated mammalian cell to be used as a source of donor nuclei or donor cell nucleus is a non-quiescent somatic cell-or a nucleus isolated from said non-quiescent somatic cell.
- 11-13. (Canceled)
- 14. (Currently Amended) The method of claim 1, further comprising using a second selective agent.
- 15-16. (Canceled)

Serial No.: 10/619055 - 4 - Art Unit: 1632

Conf. No.: 6885

17. (Currently Amended) The method of claim 1, wherein cytocholasin-B is not used in the eloning protocol.

18-21. (Canceled)

22. (Original) The method of claim 1, wherein the desired gene codes for a biopharmaceutical protein product.

23. (Currently Amended) The method of claim 22, wherein said biopharmaceutical protein product is a compound selected from the group consisting of: antithrombin III, lactoferrin, urokinase, PF4, alpha-fetoprotein, alpha-1-antitrypsin, C-1 esterase inhibitor, decorin, interferon, ferritin, transferrin conjugates with biologically active peptides or fragments thereof, human serum albumin, prolactin, CTFR, blood factor X, blood Factor VIII, as well as or a-monoclonal antibodyies.

24. (Original) The method of claim 1, wherein the DNA construct containing the desired gene is actuated by at least one beta casein promoter.

25. (Canceled)